Schadendorf, D., Gutzmer, R., Robert, C., Lebbe, C., Liszkay, G., Svane, I. M., . . . Vecchio, M. D. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. BMJ Publishing Group.
Chicago Style (17th ed.) CitationSchadendorf, Dirk, et al. Overall Survival at 5 Years of Follow-up in a Phase III Trial Comparing Ipilimumab 10 Mg/kg with 3 Mg/kg in Patients with Advanced Melanoma. BMJ Publishing Group.
MLA (9th ed.) CitationSchadendorf, Dirk, et al. Overall Survival at 5 Years of Follow-up in a Phase III Trial Comparing Ipilimumab 10 Mg/kg with 3 Mg/kg in Patients with Advanced Melanoma. BMJ Publishing Group.
Warning: These citations may not always be 100% accurate.